about
Association of the mtDNA m.4171C>A/MT-ND1 mutation with both optic neuropathy and bilateral brainstem lesionsFree Mg2+ concentration in the calf muscle of glycogen phosphorylase and phosphofructokinase deficiency patients assessed in different metabolic conditions by 31P MRSMutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorderSyndromic parkinsonism and dementia associated with OPA1 missense mutationsDiffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's diseaseImaging brain functional and metabolic changes in restless legs syndrome.Versatile coil design and positioning of transverse-field RF surface coils for clinical 1.5-T MRI applications.Brain magnetic resonance metabolic and microstructural changes in adult-onset autosomal dominant leukodystrophy.Diffusion-weighted imaging study of patients with essential tremor.Visual system involvement in patients with Friedreich's ataxia.Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease.Pitfalls and advantages of different strategies for the absolute quantification of N-acetyl aspartate, creatine and choline in white and grey matter by 1H-MRS.Clinical and neuroimaging evidence of interictal cerebellar dysfunction in FHM2.Brain and muscle energy metabolism studied in vivo by 31P-magnetic resonance spectroscopy in NARP syndromeAbnormal medial thalamic metabolism in patients with idiopathic restless legs syndrome.Secondary post-geniculate involvement in Leber's hereditary optic neuropathyFriedreich's ataxia: from disease mechanisms to therapeutic interventions.Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.Energy metabolism in migraine.Cybrid studies establish the causal link between the mtDNA m.3890G>A/MT-ND1 mutation and optic atrophy with bilateral brainstem lesions.Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study.Combined brain voxel-based morphometry and diffusion tensor imaging study in idiopathic restless legs syndrome patients.Magnetic resonance imaging and spectroscopy in the evaluation of neuromuscular disorders and fatigue.Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study.A combined a-EEG and MR spectroscopy study in term newborns with hypoxic-ischemic encephalopathy.The 13042G --> A/ND5 mutation in mtDNA is pathogenic and can be associated also with a prevalent ocular phenotype.Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy.'Behr syndrome' with OPA1 compound heterozygote mutations.Homozygous NOTCH3 null mutation and impaired NOTCH3 signaling in recessive early-onset arteriopathy and cavitating leukoencephalopathy.Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.Spinocerebellar ataxia type 12 identified in two Italian families may mimic sporadic ataxia.Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache.Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia.Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study.A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin.Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-Richardson syndrome and Parkinson disease.Abnormal brain energy metabolism shown by in vivo phosphorus magnetic resonance spectroscopy in patients with chronic liver disease.Impairment of brain and muscle energy metabolism detected by magnetic resonance spectroscopy in hereditary spastic paraparesis type 28 patients with DDHD1 mutations.Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.Abnormal cardiac energetics in patients carrying the A3243G mtDNA mutation measured in vivo using phosphorus MR spectroscopy.
P50
Q21093316-6159B8D2-0DD7-498E-B6DA-2249C7515449Q24814834-6C854383-71C6-4AA8-82FB-46842142E87CQ28117097-2C306E9E-9597-4C12-9C47-F8290C27432CQ28259640-E5B0ED03-2C34-488F-8996-FD7A9271D8E7Q28295298-4F5FCEF0-985E-4A20-8C4D-50C7232F7F68Q30656967-4265A85B-3595-4377-B7C4-19192E624347Q30979497-9DFE3410-24BD-43CE-B288-070CBF03F24AQ30981396-39C6F0EE-2F64-4B40-8AF7-A4DAFB6A6A0EQ31110931-6D9F2370-6B6C-48E0-A24F-BC5A63BFB28AQ33377900-A76C08A3-CDA2-4C22-8BFC-0E021BE087C0Q33432509-0E5C1EAA-3D31-4D1B-8005-C26378882A13Q33463544-44DECCA8-60E9-4FAA-83EA-CADA4ADC2C60Q33492954-BBB57765-FAC6-4C2C-9A58-6E6570B4BD46Q33733427-EEAD228C-A184-4799-B128-02B211FBB7F8Q34489088-769681C3-A5F1-44AF-A71B-6BB7DE16A5F3Q34500034-9DE6EF24-B30D-4597-ADD9-382A50C5306DQ34522239-CD65F17E-F609-4180-A8DC-2BA673771479Q35653693-3610B10D-F410-4DA6-9495-31BC29A8E78DQ36475097-A494C90B-5B4C-4DED-B3E8-610078586CE3Q37187580-7326B0DB-9558-4A0E-B579-F60C9DD2F492Q37381065-57F588C4-4422-40F3-8046-30E1BC97829FQ37969177-F99FCF9E-2922-4FFE-95F8-254B85D80297Q38062687-AFA5C795-03F7-4EAA-8D4A-27A04911035CQ38953697-F9C2A229-2A48-4779-B4E8-3D52BC739A0EQ39911281-DDCB3739-1A73-45AA-B16C-D48EB51E50A7Q42037621-4B7A404B-8372-43DF-A0C0-962C8DE8E4F9Q42276780-E4423480-491F-4008-A3BC-C8D5F1DDF8A7Q42538852-A3E66958-87D2-4BA8-B532-E8C16AA24784Q42579948-2AADC7E9-7108-490A-94F3-7A61B7DC325BQ42653222-07F25491-E276-4435-8385-EE242441F73BQ42668081-38486011-F9EC-40E6-86FD-2E47D3F44C64Q43577841-7CD8BAB9-22A1-4AD5-9226-BD76C9C9B8BFQ43611551-5415EB61-CF6A-400E-ADFD-D65BCA1F9F31Q43737617-EA275E7E-C749-492E-AFA8-9B905071261BQ43860533-30359999-56C6-4A8E-8017-31513261585AQ43899144-F3FA476C-7E8F-4BF8-A2F0-E327155F6369Q44173979-BD491CCE-FBC5-47AE-9A62-E4E4EBF6BF1AQ44447343-E1BBA896-442D-4AA4-95E9-744455E17768Q44698492-90D1AF4C-4CDB-4A47-82B1-5B07F84D5195Q44967212-7ADF17DB-177A-4A08-AB02-0E2F0D195213
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raffaele Lodi
@ast
Raffaele Lodi
@en
Raffaele Lodi
@es
Raffaele Lodi
@nl
Raffaele Lodi
@sl
type
label
Raffaele Lodi
@ast
Raffaele Lodi
@en
Raffaele Lodi
@es
Raffaele Lodi
@nl
Raffaele Lodi
@sl
prefLabel
Raffaele Lodi
@ast
Raffaele Lodi
@en
Raffaele Lodi
@es
Raffaele Lodi
@nl
Raffaele Lodi
@sl
P106
P1153
7006552946
P21
P31
P496
0000-0003-3878-304X